MedTrace Logo

Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm

NCT01259557 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2012-04-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Meditoxin® in the treatment of Essential blepharospasm.

Conditions

  • Essential Blepharospasm

Interventions

DRUG

Botulinum Toxin Type A

2 times, Intra-muscular injection, Maximum dosage total 60U

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Principal Investigators

  • Jaechan Kim, M.D., Ph.D. · Chung-Ang university Yongsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-05-31
Completion
2011-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01259557 on ClinicalTrials.gov